Logo
x

Search

Subscribe Now

Chronic Spontaneous Urticaria

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urtica...

  • July 29, 2021
Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

  • December 14, 2018
Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Dermatologic Indications

    Incyte and China Medical System Sign a Collaboration & License Agreement for Povorcitinib Use in Autoimmune and Inflammatory Derma...

    • April 2, 2024
    Evommune and Maruho Expand their Partnership for the Development and Commercialization of EVO756 in Greater China and Asian Countries

      Evommune and Maruho Expand their Partnership for the Development and Commercialization of EVO756 in Greater China and Asian Countr...

      • March 21, 2024
      Longbio Pharma Highlights Results from the P-I Study of LP-003 for Treating Chronic Spontaneous Urticaria at AAD 2024

        Longbio Pharma Highlights Results from the P-I Study of LP-003 for Treating Chronic Spontaneous Urticaria at AAD 2024

        • March 13, 2024
        Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

          Celltrion Submits BLA to the US FDA for CT-P39 (Biosimilar, Xolair)

          • March 11, 2024
          Sanofi Highlights Results from the P-II Trial of Rilzabrutinib for the Treatement of Chronic Spontaneous Urticaria (CSU) at AAAAI 2024

            Sanofi Highlights Results from the P-II Trial of Rilzabrutinib for the Treatement of Chronic Spontaneous Urticaria (CSU) at AAAAI...

            • February 26, 2024
            Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic Spontaneous Urticaria

              Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic...

              • October 3, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.